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D
evelopment experts and policy 
makers agree that investment 
in science and technology is 
important for economic growth and 
development. The 2001 United Nations 
(UN) Development Programme 
report, Making New Technologies Work 
for Human Development, identiﬁ  ed 
technical progress as the largest 
factor in reducing mortality rates and 
improving life expectancy from 1960 
to 1990 [1]. A May 2004 report to UN 
Secretary-General Koﬁ   Annan from 
the InterAcademy Council on Science 
and Technology Capacity supports 
the view that mobilization of sound 
scientiﬁ  c knowledge and evidence-
based principles is needed to address 
critical world issues such as poverty, 
disease, and the effects of globalization 
and economic transformation [2]. 
Annan himself has drawn attention to 
the importance of science capacity for 
global development, observing that “no 
nation can afford to be without its own 
[science and technology] capacity” [3]. 
This capacity is essential if the world 
is to achieve the UN Millennium 
Development Goals (MDGs), which 
were adopted by all UN members in 
2000 in a commitment to promote 
sustainable development and eliminate 
poverty in the world. As part of the 
Millennium Project, the UN established 
task forces to come up with strategies 
to help developing countries achieve 
the MDGs. One of these is the Task 
Force on Science, Technology, and 
Innovation (Task Force 10), created 
in recognition of the fact that many of 
the goals, especially those related to 
health and the environment, cannot be 
realized without a strong contribution 
from science and technology [4]. 
In a report titled Genomics and Global 
Health, presented recently to Task 
Force 10, we addressed how genomics 
and related health biotechnologies can 
improve global health and contribute 
towards meeting the MDGs [5]. The 
report shows how the world can unite 
in a global approach to meet these 
objectives and what steps developing 
countries themselves are taking to 
harness these technologies. The main 
ﬁ  ndings of the report are summarized 
in our conclusions below.
Genomics Can Contribute to the 
MDGs
Genomics refers to the powerful new 
wave of health-related life sciences 
energized by the human genome 
project and the knowledge and tools it 
is spawning. It is a relatively new science 
that has tremendous potential to 
address health problems in developing 
countries. 
The role of genomics in global 
health has been highlighted previously 
in the World Health Organization’s 
2002 report [6], and explored further 
in a technology foresight exercise 
by the University of Toronto Joint 
Centre for Bioethics [7]. Genomics-
related technologies, including DNA 
sequencing and bioinformatics, were 
once considered expensive, exotic, 
and applicable only to wealthy nations, 
but this perception has been changing 
over the past few years. Through the 
efforts of companies and institutions 
worldwide, certain applications have 
become simpler and cheaper to the 
point that they can start replacing 
older technologies that are currently 
used for health care in poorer nations. 
Such simple and easy-to-use tests are 
being developed for tuberculosis, 
hepatitis C, HIV, malaria, and other 
diseases (e.g., the OptiMAL rapid 
malaria test [http:⁄⁄www.malariatest.
com/]). Recombinant vaccines, a result 
of genetic engineering, promise to be 
safer, cheaper, and possibly easier to 
store and transport than traditional 
vaccines [7]. Microorganisms with 
remarkable biochemical properties 
show promise of being able to reduce 
pollution, making water safer to drink 
[8]. Table 1 provides a snapshot of how 
genomics and related biotechnologies 
can support some important MDGs 
[9]; a more complete discussion can be 
found in our report [5].
What the International Community 
Can Do 
In Genomics and Global Health [5], 
we argue that genomics knowledge 
should be considered a global public 
good [10]. We need to establish a 
governance mechanism that fosters a 
balance between genomics knowledge 
as a public good and the application of 
this knowledge to foster private-sector 
interests. We propose the creation 
of a global partnership, the Global 
Genomics Initiative (GGI), to promote 
genomics for health. We see this as a 
network of industry leaders, academics, 
concerned citizens, non-governmental 
organizations, and government ofﬁ  cials, 
with strong representation from the 
developing world. The proposed GGI 
would highlight broad actions that 
should be taken at the global level 
to apply genomics to development 
issues in this new era of globalization. 
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Participation in the GGI would 
strengthen capacity in biotechnology 
worldwide by increasing international 
and inter-sectoral exchange of know-
how, and encouraging partnerships 
between countries.
The GGI could also facilitate the 
sharing of good practices. For example, 
the Canadian Prime Minister, Paul 
Martin, in his February 2004 reply to 
the Speech from the Throne, set a 
long-term target for Canada to devote 
5% of its research and development 
spending to the challenges of 
developing countries. If successfully 
implemented and replicated by other 
industrialized countries, this target 
could make a real difference to global 
health.
What Developing Countries Can Do
Our report concludes that the key 
actors are developing countries 
themselves. We explore how to put 
genomics and related technologies to 
work in developing countries within 
the next 5–10 years. Developing 
countries with the scientiﬁ  c capacity 
and institutional arrangements that 
allow creation, utilization, adaptation, 
and diffusion of genomics are well 
positioned to harness this new science 
for development (Figure 1). Learning 
is important for building genomics 
capacity, and is central to the creation 
of national systems of innovation 
(NSIs) in biotechnology in developing 
countries. 
Today there are examples of 
strategies that some developing 
countries, including China, Cuba, 
Brazil, India, and South Africa, have 
followed to institute learning processes 
that are helping them to build NSIs 
in biotechnology. China seized the 
opportunity to take part in the Human 
Genome Project and quickly set up 
major institutions in genomics, such 
as the Beijing Genomics Institute, 
equipped with state-of-the-art 
sequencing facilities and computers. It 
has also followed a strategy of private-
sector development in line with the NSI 
framework. Because of a government 
policy encouraging their return, 
Chinese expatriates are increasingly 
active in setting up small health 
biotechnology ﬁ  rms, bringing to the 
country knowledge from the world’s 
major centers for genomics and related 
technologies. 
The government in Cuba became 
interested in biotechnology in 
the early 1980s when the ﬁ  eld was 
still in its infancy and created an 
interdisciplinary group, the Biological 
Front, to explore the possibilities of the 
technology for Cuba. It has continued 
to support biotechnology even during 
periods of economic hardship, 
set up institutions with research, 
development, and manufacturing 
facilities, and encouraged linkages 
between these institutions by setting 
up a biotechnology cluster, the West 
Havana Scientiﬁ  c Pole. Encouraging 
linkages has been a core policy of the 
government in Cuba, and its health 
biotechnology development has 
beneﬁ  ted from the ties with a strong 
public health system. 
Brazil has a relatively long history 
of supporting science and technology, 
and the country is increasingly focusing 
on genomics and related technologies. 
The lack of commercialization of its 
cutting edge science and technology 
has been a weakness of the system in 
Brazil, but the country is now trying to 
overcome this weakness by proposing 
an “Innovation Law” that encourages 
cooperation between universities and 
the private sector.
Since its independence in 1947, 
India has followed a vision to improve 
the quality of life of its people by 
emphasizing science and technology. 
Limited resources and a patenting 
system that did not allow patenting 
of pharmaceutical products but only 
Table 1. Genomics and Related Biotechnologies Can Support the MDGs
MDG Statistics/Facts Biotechnology to Address MDG
Goal 3: Promote gender equality 
and empower women
In 2001, 57% of HIV cases in 
sub-Saharan Africa were women. 
Average HIV infection rates in 
teenage girls are ﬁ  ve times higher 
than those in teenage boys [11]
•  Female control over STD 
transmission protection
•   Vaccine and drug delivery
Goal 4: Reduce child mortality About 11 million children die 
before reaching their ﬁ  fth 
birthday [12] 
• Molecular  diagnostics
•  Vaccine and drug delivery
• Recombinant  vaccines
•  Female control over STD 
transmission protection
•  Nutritionally enriched GM crops
• Combinatorial  chemistry
Goal 5: Improve maternal health Over 500,000 maternal deaths 
per year 
• Molecular  diagnostics
•  Vaccine and drug delivery
• Recombinant  vaccines
•  Female control over STD 
transmission protection
•  Nutritionally enriched GM crops
• Combinatorial  chemistry
Goal 6: Combat HIV, malaria, and 
other diseases
HIV/AIDS, malaria, and 
tuberculosis are responsible 
for more than 6 million deaths 
worldwidea 
• Molecular  diagnostics
•  Vaccine and drug delivery
• Recombinant  vaccines
•  Female control over STD 
transmission protection
•  Bioremediation (using living 
organisms to degrade/transform 
hazardous organic contaminants)
•  Sequencing pathogen genomes
• Bioinformatics
•  Enriched GM crops
• Combinatorial  chemistry
Goal 7: Ensure environmental 
sustainability
5 million deaths per year can be 
attributed to waterborne diseases 
[13]
• Bioremediation
a Source: Global Fund to Fight AIDS, Tuberculosis, and Malaria (http://www.theglobalfund.org). 
GM, genetically modiﬁ  ed; STD, sexually transmitted disease.
DOI: 10.1371/journal.pmed.0010040.t001
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patenting of processes encouraged 
ﬁ  rms to come up with low-cost process 
innovation. This has resulted in 
health products such as the Shanvac-B 
hepatitis B vaccine, which is produced 
in India for a fraction of the cost in 
developed countries.
The South African government’s 
Biotechnology Advisory Committee 
recognizes that successful 
commercialization of public-sector-
supported research and development 
requires strong linkages within the 
NSI. The committee has recommended 
the creation of several Regional 
Innovation Centres to act as nuclei 
for the development of biotechnology 
platforms that can effectively launch 
new products and services. These 
strategies will provide important lessons 
for many other developing nations 
as they begin participating in the 
genomics revolution.
Six Conclusions to Our Report
First, the development gap between 
developing countries and the 
industrialized world continues to 
grow. The international community 
is beginning to promote science and 
technology to reduce this gap. The 
genomics revolution holds tremendous 
potential to improve health in 
developing countries and, if harnessed 
appropriately, could help to reduce the 
development divide.
Second, genomics and related 
biotechnologies can help to achieve 
the UN MDGs. Fast, accurate molecular 
diagnostic devices, safer recombinant 
vaccines, female-controlled 
vaginal microbicides, and low-cost 
bioremediation tools 
are some examples of 
biotechnologies that can 
have an impact.
Third, genomics 
knowledge has the 
characteristics of a 
global public good. In 
order to harness the 
beneﬁ  ts of genomics 
for development, the 
developing world needs, 
above all, access to 
genomics knowledge. 
Fourth, the promotion 
of the science of genomics 
as a global public good 
and the encouragement 
of global knowledge ﬂ  ows could best 
be achieved through international 
partnerships. A GGI involving an 
international partnership of public and 
private entities from both developed 
and developing countries could 
catalyze genomics knowledge and 
learning worldwide.
Fifth, countries that have genomics 
capacity are best positioned to take 
advantage of the genomics revolution 
to meet their health needs. For 
the transfer of technologies to be 
effective and sustainable, it must be 
accompanied by transfer of science and 
knowledge. As well, receiving countries 
must have the capacity to absorb and 
use the technology.
And sixth, learning is important 
for building genomics capacity, and 
is central to the creation of NSIs in 
biotechnology in developing countries. 
These countries can strengthen the 
building blocks of the NSI framework 
by doing the following: re-energizing 
academic institutions and public-sector 
research to strengthen their science 
base; training people and building 
human capital to use, adapt, and 
innovate biotechnologies; encouraging 
regional and international cooperation 
to create new channels for knowledge 
exchange and trade; improving 
the policy environment (including 
intellectual property laws and 
regulation) to encourage the building 
of capacity; and fostering the growth 
of the private sector, encouraging it 
to address local health needs, and 
strengthening linkages between public 
and private sectors to create new 
biotechnology goods and services.  
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Figure 1. A Rapid Test for HIV Used in Jaipur, India
Biotechnology has a vital role to play in developing better 
diagnostic tools for diseases such as HIV, tuberculosis, and 
malaria. (Photo: World Health Organization/P. Virot)